Journal article
Rgs6 is required for adult maintenance of dopaminergic neurons in the ventral substantia nigra
PLoS genetics, Vol.10(12), pp.e1004863-e1004863
12/2014
DOI: 10.1371/journal.pgen.1004863
PMCID: PMC4263397
PMID: 25501001
Abstract
Parkinson disease (PD) is characterized by the preferential, but poorly understood, vulnerability to degeneration of midbrain dopaminergic (mDA) neurons in the ventral substantia nigra compacta (vSNc). These sensitive mDA neurons express Pitx3, a transcription factor that is critical for their survival during development. We used this dependence to identify, by flow cytometry and expression profiling, the negative regulator of G-protein signaling Rgs6 for its restricted expression in these neurons. In contrast to Pitx3-/- mDA neurons that die during fetal (vSNc) or post-natal (VTA) period, the vSNc mDA neurons of Rgs6-/- mutant mice begin to exhibit unilateral signs of degeneration at around 6 months of age, and by one year cell loss is observed in a fraction of mice. Unilateral cell loss is accompanied by contralateral degenerating neurons that exhibit smaller cell size, altered morphology and reduced dendritic network. The degenerating neurons have low levels of tyrosine hydroxylase (TH) and decreased nuclear Pitx3; accordingly, expression of many Pitx3 target gene products is altered, including Vmat2, Bdnf, Aldh1a1 (Adh2) and Fgf10. These low TH neurons also express markers of increased dopamine signaling, namely increased DAT and phospho-Erk1/2 expression. The late onset degeneration may reflect the protective action of Rgs6 against excessive DA signaling throughout life. Rgs6-dependent protection is thus critical for adult survival and maintenance of the vSNc mDA neurons that are most affected in PD.
Details
- Title: Subtitle
- Rgs6 is required for adult maintenance of dopaminergic neurons in the ventral substantia nigra
- Creators
- Panojot Bifsha - Laboratoire de Génétique Moléculaire, Institut de Recherches Cliniques de Montréal (IRCM) Montréal, Quebec, Canada; Division of Experimental Medicine, McGill University, Montréal, Quebec, CanadaJianqi Yang - Department of Pharmacology, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States of AmericaRory A Fisher - Department of Pharmacology, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States of AmericaJacques Drouin - Laboratoire de Génétique Moléculaire, Institut de Recherches Cliniques de Montréal (IRCM) Montréal, Quebec, Canada; Division of Experimental Medicine, McGill University, Montréal, Quebec, Canada
- Resource Type
- Journal article
- Publication Details
- PLoS genetics, Vol.10(12), pp.e1004863-e1004863
- DOI
- 10.1371/journal.pgen.1004863
- PMID
- 25501001
- PMCID
- PMC4263397
- NLM abbreviation
- PLoS Genet
- ISSN
- 1553-7390
- eISSN
- 1553-7404
- Publisher
- Public Library Science; United States
- Grant note
- MOP-123213 / Canadian Institutes of Health Research CA161882 / NCI NIH HHS R01 CA161882 / NCI NIH HHS
- Language
- English
- Date published
- 12/2014
- Academic Unit
- Iowa Neuroscience Institute; Neuroscience and Pharmacology; Internal Medicine
- Record Identifier
- 9984040016302771
Metrics
17 Record Views